Publications by authors named "K A Kreuzer"
Purpose: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies.
Methods: The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group.
Article Synopsis
- Bacteriophage T4's gp32 protein is crucial for DNA processing, as it binds to single-stranded DNA (ssDNA) to protect it and help initiate DNA replication and repair.
- Researchers purified and crystallized the gp32-Dda-ssDNA complex, revealing how gp32's C-terminus interacts with the Dda helicase, shedding light on the structural details of this interaction.
- The study confirmed through various analyses, including DNA unwinding assays, that gp32 effectively sequesters ssDNA produced by Dda, outlining important functions of the gp32-Dda interaction in DNA processing.
In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n = 216). Progression-free survival (PFS) was the primary end point. Key secondary end points included time-to-next-treatment (TTNT), rates of undetectable minimal residual disease (uMRD), overall survival (OS), and rates of adverse events.
View Article and Find Full Text PDFArticle Synopsis
- The GAIA/CLL13 trial found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib combinations led to better undetectable measurable residual disease (MRD) rates and longer progression-free survival compared to traditional chemoimmunotherapy for untreated chronic lymphocytic leukaemia (CLL) patients.
- The trial was a phase 3 study involving 159 sites across Europe and the Middle East, enrolling patients aged 18 and older with specific health criteria and assigning them to different treatment groups, including standard chemoimmunotherapy and various venetoclax-based combinations.
- All treatment regimens were administered in cycles, with detailed protocols for each group, specifically focusing on